Compound hub · BPC-157
BPC-157 side effects: what the studies report
The FDA judged the clinical safety data on BPC-157 too thin to set out a side-effect profile (FDA, July 2026). Its five human studies had 2 to 53 people each. They appear to report no serious adverse events, but their safety reporting is limited (FDA, July 2026). In 28-day rat and dog tests, clotting and liver-enzyme changes raised safety signals. The FDA summary gives no group sizes, and the signals do not show effects in humans (Xu et al., 2020, via FDA, July 2026).
01Safety recordContents
- 01Safety record
- 02Human studies
- 03FDA's view
- 04Reported events
- 05Australian reports
- 06Tablets and capsules
- 07Women, men and pregnancy
- 08Liver
- 09Liver records
- 10Kidney evidence
- 11Heart and blood pressure
- 12Blood clots
- 13Clotting directions
- 14Blood vessels and cancer
- 15Knee, meniscus, cartilage, disc
- 16Three evidence lists
- 17Exposure and follow-up
- 18What is not known
- 19Research material
- Comparison
- FAQ
- Sources
Every approved medicine ships with a list of side effects. Every line on that list was earned by watching real people over time. Nurses, trial staff and doctors wrote down each headache, rash and abnormal blood test until patterns showed up. That slow, plain work is what a safety profile is. For BPC-157, most of it has not been done yet.
This page reads the records that do exist. They range from small human pilot reports to the FDA's July 2026 briefing document, TGA documents and animal toxicity studies. It says what each one can and cannot show. It sits inside the BPC-157 hub, next to pages on what the studies have found and how BPC-157 and TB-500 differ. It describes studies and gives no advice.
Key facts
| Compound | BPC-157, a 15-amino-acid peptide (sequence GEPPPGKPADDAGLV) |
|---|---|
| Published human safety reports | Five small studies: three pilot reports (2021, 2024, 2025) and two studies reported only as meeting abstracts (FDA, July 2026). |
| Published pilot designs | 17 knee charts (16 contacted), 12 women with interstitial cystitis and 2 adults with prior exposure. All were uncontrolled (FDA, July 2026). |
| Randomised controlled trial papers | The PubMed search run for this page on 14 October 2026 did not find one. |
| Longest repeated human exposure in the FDA's list | Two weeks, in a meeting-abstract study of 53 adults with ulcerative colitis, randomised 1:1 to BPC-157 or placebo (FDA, July 2026). |
| FDA adverse-event reports (FAERS) | 3 voluntary reports through 4 December 2025. The FDA could not say BPC-157 caused any of them (FDA, July 2026). |
| FDA compounding position | FDA staff proposed against adding BPC-157 to the 503A bulks list (FDA, July 2026). |
| Approved product in any country | No approved product containing BPC-157 appeared in the FDA's globalEDGE search (FDA, July 2026). |
| TGA position | Named as an example of an unapproved peptide product (TGA, 13 April 2026). |
Is BPC-157 safe, and what side effects have studies reported?
No one can yet say that BPC-157 is safe, because the safety record is too thin. The FDA's July 2026 review judged the clinical safety information insufficient to set out a profile. In its July 2026 briefing document, the FDA listed five small human studies of 2 to 53 people each. It saw no sign that serious adverse events were reported in them. It also noted their short length, small samples and limited safety data (FDA, July 2026). The most common minor events in the healthy-volunteer abstracts were headache and flatulence. Those abstracts covered 32 male volunteers (24 given BPC-157). The events happened about as often on placebo (Veljaca et al., meeting abstracts, 2002 and 2003, as tabulated by the FDA). A quiet record is not a clean record.
Why does a record with no reported problems still count as unfinished? Such small studies cannot reliably estimate how often events happen. They also cannot rule out rare harms. A 2025 review covered three pilots: a 17-chart knee review with 16 patients contacted, a bladder pilot in 12 women, and a pilot in two adults. It reported no adverse effects. But small uncontrolled studies cannot show safety (McGuire et al., 2025). You can read more about the compound itself in the BPC-157 research guide.
That gap also answers the many questions about how long exposure lasts. The FDA's list of five human studies records repeated exposure for two weeks at most. Those were meeting-abstract studies of 32 healthy volunteers and 53 adults with ulcerative colitis. The abstracts have incomplete methods and limited safety reporting. The review calls the information on long-term use insufficient (FDA, July 2026).
What did the published human studies of BPC-157 record about side effects?
The published human studies of BPC-157 record almost no side effects, but they are small. The FDA's review lists five small human studies of 2 to 53 people each, with limited safety reporting. No serious adverse event appears to have been reported in any of them (FDA, July 2026). A 2021 chart review looked back at 17 people with knee pain, with no control group. The authors wrote that no adverse events were noted (Lee and Padgett, 2021, as quoted by the FDA). A 2024 pilot covered 12 women with interstitial cystitis, a bladder-pain condition, with no control group. No one dropped out and no adverse events were reported (Lee et al., 2024). A 2025 pilot covered two adults who had used BPC-157 before. It cannot show safety. The authors reported no measurable effects on heart, liver, kidney, thyroid or blood-glucose markers (Lee and Burgess, 2025). The table below lists each study with its limits.
Read those lines with care. The knee study looked back at clinic charts and phoned patients six months to a year later. So anything forgotten went unrecorded (Lee and Padgett, 2021). The bladder pilot had no control group, so nothing in it can be set against placebo (Lee et al., 2024). The 2025 pilot had two participants, and both had used BPC-157 before the trial began (Lee and Burgess, 2025).
All three papers share a lead author, Lee E. All were run in Florida clinics with BPC-157 made by United States compounding pharmacies (FDA, July 2026). Independent replication would carry more weight, and none was found for this page.
What does the FDA say about BPC-157 safety?
The FDA says it lacks enough information to know whether BPC-157 would cause harm in humans. Its page on bulk drug substances that may present significant safety risks, current as of 22 April 2026, lists BPC-157 among substances that were put forward and then withdrawn. It warns about immunogenicity, which is an unwanted immune reaction, and about peptide-related impurities (FDA, April 2026). In its July 2026 briefing document, FDA staff proposed not adding BPC-157 to the list of substances pharmacies may compound. They cited missing safety data, the risk of immune reactions, and too little evidence for ulcerative colitis (FDA, July 2026).
An advisory committee then met on 23 July 2026. The Regulatory Affairs Professionals Society reported that it "voted 8-6 with one abstention" to recommend adding two peptides to the 503A bulks list: BPC-157 for ulcerative colitis, and KPV (RAPS, 23 July 2026). The FDA's meeting page carries no vote result. It says advisory committees make non-binding recommendations. The FDA's briefing states that it will make no final decision until it has weighed the committee's input and finished all reviews (FDA, July 2026). A vote on a list is a decision about pharmacy compounding. It is not an approval. The FDA's briefing records that a globalEDGE search found no approved product containing BPC-157 in any country (FDA, July 2026).
The FDA also named what the human record lacks. Its search found no human studies of the routes put forward for compounding. It saw no information on how the body absorbs the peptide by those routes (FDA, July 2026).
What adverse events have been reported to regulators for BPC-157?
Three adverse-event reports for BPC-157 reached the FDA's reporting system, FAERS, through 4 December 2025. The FDA could not say that BPC-157 caused any of them (FDA, July 2026). In the FDA's summary, a 55-year-old woman reported nine days of redness and swelling where a product was given. She was also using a thymosin product. A 28-year-old man reported shortness of breath that led to an emergency visit, with no further detail. A 40-year-old woman reported darkened skin and gums that returned when she tried a BPC-157 and TB-500 product again. All three are voluntary reports, and they do not show cause (FDA, July 2026).
Reports like these are signals, not measurements. People file them voluntarily. The FDA says it cannot reach firm conclusions about safety from FAERS alone (FDA, July 2026). Its food-complaint search through 3 December 2025 found three cases that involved multi-ingredient BPC-157 supplements. These are voluntary reports, and they cannot show which ingredient caused a reaction (FDA, July 2026). The FDA's own PubMed and Embase search found no published BPC-157 case reports (FDA, July 2026).
Clinical reviews say much the same. A 2025 systematic review in HSS Journal covered 36 studies, and 35 of them were preclinical. It found no clinical safety data. It warned that adverse effects remain possible because of unregulated making, contamination or unknown clinical safety (Vasireddi et al., 2025).
What side effects has the TGA recorded for unapproved peptide products?
The TGA has recorded adverse events and other concerns for unapproved peptide products as a group. It has not tied them to BPC-157 alone. Its 13 April 2026 advisory lists these reports: severe allergic reactions needing adrenaline and hospital care, a body-wide inflammatory reaction, widespread itching, palpitations, insomnia, blurred vision, extreme tiredness, joint pain, and tendon injuries such as Achilles tendinitis. They are for products whose contents the TGA could not verify. The advisory gives no case count and ties nothing to BPC-157 (TGA, 13 April 2026). A joint statement from the TGA and the Chief Medical Officer on 19 June 2026 listed liver damage for unapproved peptides as a group. It gave no case counts and tied nothing to BPC-157 (TGA and CMO, 19 June 2026).
The advisory names BPC-157 as one example beside GHK-Cu, TB-500, retatrutide and CJC-1295. The reports are about products whose contents the TGA could not verify. So its text does not say whether any reaction came from the peptide, a contaminant or another ingredient. The TGA says it is still unknown how these products work in the body and what side effects they may cause (TGA, 13 April 2026).
How Australian law treats BPC-157 has its own guide, BPC-157 and the Poisons Standard. This page does not repeat it.
What is known about the side effects of BPC-157 tablets and other oral forms?
Almost nothing is known. The FDA's July 2026 review found no human study of oral BPC-157 that reported side effects. The one registered oral trial, NCT02637284, has no posted results (FDA, July 2026). That Phase 1 trial listed 42 planned healthy volunteers aged 18 to 35, with adverse events as the primary outcome. Its record was last updated in December 2015 (ClinicalTrials.gov). Its status is listed as unknown, and the FDA review says it could not find an associated published study.
The FDA review reports that BPC-157 resisted breakdown in human gastric juice in vitro, which means in a test tube. Its summary gives no sample count. This lab finding does not show human absorption or safety (FDA, July 2026). A 2026 narrative review describes the human pharmacokinetic profile as critically undercharacterised (Mateescu et al., 2026).
The FDA judged the immune-reaction risk of an oral peptide likely to be low. It stayed concerned about peptide-related impurities in any product form (FDA, July 2026).
Do BPC-157 side effects differ in women or men, or in pregnancy?
No study has been found that sorts BPC-157 side effects by sex or covers pregnant people. The FDA briefing and the PubMed records searched for this page on 14 October 2026 hold none. Women made up the whole 12-person bladder pilot. It had no control group and reported no adverse events (Lee et al., 2024). Two of the three FDA adverse-event reports came from women (FDA, July 2026). The only pregnancy-related data found are from rats. In a 2020 study, the FDA's summary says BPC-157 had no effect on the number of live fetuses, fetal weight or malformations. The FDA summary does not give the group size. The result does not carry over to people, and it did not cover a full reproductive cycle (Xu et al., 2020, as summarised by the FDA in July 2026).
A rat result does not carry over to pregnant women. The FDA noted that the 2020 study did not follow a full reproductive cycle, from conception through the next generation (FDA, July 2026). On 14 October 2026, a PubMed search paired BPC-157 with pregnancy terms in titles or abstracts. It returned no records.
Men are in the same position. The 2025 pilot included one man and one woman. No published report found for this page separates results by sex (Lee and Burgess, 2025).
Does BPC-157 cause liver damage or liver problems?
No liver damage from BPC-157 has been reported in people, but the data are too small to rule it out. The FDA's list covers five small human studies of 2 to 53 people each, and none was large enough to rule out liver harm (FDA, July 2026). In a 2025 pilot of two adults, liver markers did not change measurably. A two-person pilot cannot show safety (Lee and Burgess, 2025). Rats and dogs were tested for 28 days. Neither the FDA summary nor the paper's abstract gives group sizes. FDA reviewers flagged liver-related signals: higher ALT, a liver enzyme, plus higher glucose and triglycerides. These findings are in animals and do not describe humans (FDA, July 2026, summarising Xu et al., 2020). A rat study went the other way. It reported smaller liver lesions after a toxic drug challenge. The abstract does not give the group size, and the animal finding does not show a human result (Ilic et al., 2011). The TGA lists liver damage among harms linked to unapproved peptides in general (TGA and CMO, 19 June 2026).
Mixed signals are normal at this stage of research. The same 28-day paper that the FDA reads as raising flags described BPC-157 as well tolerated overall in mice, rats, rabbits and dogs. The abstract does not give group sizes. This animal finding does not describe humans (Xu et al., 2020). That is how two careful readers can look at one dataset and disagree. A longer toxicity study that follows the guidelines could help explain the gap. A 2026 review notes that none has been reported in a form regulators would accept (Mateescu et al., 2026).
Why do some pages say BPC-157 protects the liver and others say it stresses it?
The pages draw on studies that asked different questions about BPC-157. The FDA's July 2026 review describes rat tests with planned liver injury. It also flags liver blood-test changes in separate animal safety tests. Lee and Burgess found no measured liver-test changes in two adults in 2025. None of these records settles liver safety in people.
In the injury tests, rats received BPC-157 before the liver challenge. The FDA says the result after an injury remains unknown. That order matters when reading a claim about liver protection.
The separate animal safety tests raised concerns about liver-related blood markers. A marker is a measured clue, rather than a diagnosis. The small human pilot cannot rule out liver harm.
Is BPC-157 hard on the kidneys?
The opened BPC-157 records cannot settle kidney safety in people. Lee and Burgess reported no measured kidney-test changes in two adults in 2025. Vukoja and colleagues studied rats with kidney injury in 2026. Their findings describe that rat model. Neither record shows what happens to human kidneys over time.
Vukoja's team used gentamicin, an antibiotic that can injure the kidneys, in rats. They reported less injury with BPC-157 in that setting. This does not test kidney safety in people.
Kidney clearance means that a substance leaves the body through the kidneys. Clearance alone does not show kidney damage. A claim about harm needs its own evidence.
Can BPC-157 affect the heart, blood pressure or cholesterol?
Human data on BPC-157 and the heart are very thin. The sources searched for this page found only a two-adult pilot and a study of human artery tissue in a lab bath. A PubMed search on 14 October 2026 paired BPC-157 with cholesterol in titles or abstracts and returned no records. In a 2025 pilot of two adults, the authors reported no clinically significant change in blood pressure, heart rate or heart-related blood tests. A two-person pilot cannot show safety (Lee and Burgess, 2025, as tabulated by the FDA in July 2026). In rats, BPC-157 left normal blood pressure alone. It did change the pressure rise caused by the drug L-NAME. The abstract does not give group sizes, and the finding does not describe humans (Sikirić et al., 1997). Rings of human internal mammary artery came from 12 bypass operations. BPC-157 relaxed the vessel wall in a lab bath. This tissue finding does not show an effect in a living person (Yildirim et al., 2026).
A dish of artery tissue is a long way from a beating heart. The 2026 paper itself says more molecular and whole-body studies are needed to clarify clinical relevance (Yildirim et al., 2026). On cholesterol, the PubMed search described above returned no records. The only fat-level hint found for this page is the triglyceride rise that FDA reviewers noted in the 28-day rat and dog studies. The FDA summary does not give group sizes, and the finding in animals does not describe humans (FDA, July 2026).
Can BPC-157 cause blood clots or change how blood clots?
No human study has tested whether BPC-157 changes clotting. The FDA briefing and the PubMed records checked for this page on 14 October 2026 include none. In 28-day studies, the FDA saw a shorter clotting time in rats and a longer one in dogs. The measure was aPTT, a lab test of clotting speed. The FDA read both as signs of altered clotting properties. The FDA summary gives no group sizes, and the animal findings do not describe humans (FDA, July 2026, from Xu et al., 2020). A 2012 rat study came from the Zagreb group that produced most of the preclinical work. It found less bleeding and smaller platelet falls in rats given heparin, warfarin or aspirin. The abstract gives no group sizes, and no human study backs the finding (Stupnisek et al., 2012). A 2019 study from the same group reported that BPC-157 undid the platelet-blocking effect of aspirin, clopidogrel and cilostazol in tests on blood from rats. The abstract gives no group sizes, and no human study backs it (Konosic et al., 2019).
A 2026 review states that formal drug-interaction studies, in the lab and in living animals, are still needed (Mateescu et al., 2026).
Those animal findings do not show clot risk in people. The FDA's list of five small human studies of 2 to 53 people each has limited safety reporting. It records that no serious adverse event appears to have been reported, and its search found no published case report (FDA, July 2026).
What did the clotting tests show in rats and dogs?
The clotting test changed in opposite directions in the BPC-157 animal studies. The FDA's July 2026 review describes shorter clotting times in rats and longer times in dogs. Both findings came from 28-day safety tests. They raise questions about clotting, but do not establish clot risk in people.
The test is called aPTT. It measures how long part of the blood-clotting process takes. A shorter reading and a longer reading are different findings. Neither result can stand in for a human clotting study.

Does BPC-157 grow blood vessels, and does that raise cancer risk?
Whether BPC-157 changes cancer risk in people is unknown. Hsieh and colleagues found more vessels in a chick-membrane assay, and more tube formation in cultured human endothelial cells. They also found faster blood-flow recovery in rat hind limbs with poor supply, and higher VEGFR2, a receptor that signals vessel growth. These were lab and rat models, and the abstract gives no sample sizes. The findings do not show an effect in people (Hsieh et al., 2017). The FDA review found no carcinogenicity studies of BPC-157, which are the animal studies that test cancer risk (FDA, July 2026). A 2026 review calls this a major theoretical safety uncertainty (Mateescu et al., 2026).
People who ask whether BPC-157 makes you vascular usually mean visible veins. The FDA briefing and the PubMed records checked on 14 October 2026 found no BPC-157 study that measured vein visibility or body composition. The vessel studies above counted tiny vessels in tissue sections and cultured cells, not veins you can see.
The cancer question is disputed in print. A 2025 literature review raised concerns about vessel-growth signalling. A later comment challenged that reading. These are opposing readings of preclinical evidence, not human cancer-risk measurements (Józwiak et al., 2025; Sikirić et al., 2025).
What do studies show about BPC-157 and joint pain, meniscus tears, cartilage or a bulging disc?
The only human data on BPC-157 and joints found for this page are from a 2021 look back at 17 people with knee pain. Of the 16 reached by phone, 14 reported relief. Relief was rated by phone recall, with no validated scale, imaging or control group (Lee and Padgett, 2021). A PubMed search on 14 October 2026 found no BPC-157 paper that reported a meniscus, cartilage or intervertebral disc result in its title or abstract. A 2026 scoping review searched PubMed for six peptides. It described the human clinical studies as limited to a handful, most lacking strong controls or rigorous designs. It also described the human data as mixed (Tewari et al., 2026).
The 2021 authors called for follow-up MRI scans. Their stated potential for tissue repair is a hope, not a result. An uncontrolled report like theirs cannot separate an effect of treatment from other explanations, such as placebo response.
In the same 14 October 2026 search, the words meniscus and cartilage appeared in only a handful of BPC-157 records. The matches were reviews and the knee report's own list of possible causes of knee pain. A bulging disc returned no records.
Which side-effect list is which?
Animal lab findings, human reports and unsourced lists carry different weight for BPC-157. The FDA's July 2026 review flags blood-test changes in animals. Lee and Burgess's 2025 human pilot reports no side effects in two adults. A list without a study source cannot show which effects were measured.
Animal findings can raise questions for later human tests. Small human reports describe what staff looked for and recorded. An unsourced list leaves both the test and its limits unclear.
Ask where each item came from before reading it as a known side effect. A concern, a measured change and a reported symptom are separate kinds of evidence.
How long did the human safety records last?
The two-day BPC-157 pilot is not the longest exposure in the FDA's July 2026 list. That review records repeated human exposure up to two weeks. These longer records are meeting abstracts, with limited safety detail. Lee and Burgess's 2025 pilot checked two adults across three days. Neither record establishes long-term safety.
In the small human pilot, exposure covered two days. Blood checks continued on the next day. Exposure time and the time spent checking later are different measures.
The registered oral study has no posted results, checked 17 October 2026. Its history lists a cancelled results submission. This does not show that the trial itself was cancelled. A study plan cannot replace findings.
Evidence limits
What is still unknown about BPC-157 safety?
Five gaps stand out in the BPC-157 safety record as of 14 October 2026. First, the FDA lists a placebo-controlled phase 1 study in 32 randomised healthy volunteers and a randomised colitis study in 53 adults. Both exist only as meeting abstracts (FDA, July 2026). No full-paper randomised trial was found for this page. Second, human pharmacokinetics are not known. That means how fast the body clears the peptide. The FDA states there is no information to assess it (FDA, July 2026). Third, the FDA's list shows no repeated-exposure human data beyond two weeks (FDA, July 2026). Fourth, the FDA review found no carcinogenicity studies (FDA, July 2026). A 2026 review says it is still unknown whether BPC-157 interacts with the enzymes or carriers that handle drugs (Mateescu et al., 2026). Fifth, identity is unsettled. The FDA calls BPC-157 not well characterised in its physical and chemical profile (FDA, July 2026).
Most of the preclinical work comes from one academic group in Zagreb. The 2026 Pharmaceutics review notes that the first independent pharmacokinetic data came from a group in Xi'an, China (Mateescu et al., 2026). The 2025 HSS Journal review found 36 qualifying studies. Of these, 35 were preclinical and one was clinical (Vasireddi et al., 2025). Independent confirmation is the missing piece behind almost every question above.
Is research-use BPC-157 the material these studies tested?
The studies do not show a match. The Florida pilots above used BPC-157 made by United States compounding pharmacies. The 2002 to 2005 meeting abstracts used a developer's product coded PL 14736 (FDA, July 2026). The animal studies used lab peptide under study conditions. Research-use reference material is a lab compound. It is not a medicine, is not a substitute for one, and is not for human or animal use. The FDA found BPC-157 not well characterised from a physical and chemical view. So a name on a label does not tell a reader what any one study measured (FDA, July 2026).
The catalogue lists BPC-157 reference material as laboratory stock. A listing is a catalogue record, not evidence about any study. Reading the paperwork that comes with a batch takes some skill. The quality and verification hub explains what a certificate can and cannot show.
Comparison
This table lists human studies of BPC-157 that recorded adverse events. The list comes from the FDA's July 2026 briefing and from PubMed. Each row reports what the authors wrote, not what the data prove.
| Study | Participants | Adverse events reported | Main limit |
|---|---|---|---|
| Veljaca et al., 2002 and 2003 (meeting abstracts) | 32 healthy male volunteers; 24 received BPC-157 | In 32 healthy male volunteers (24 given BPC-157), the abstract authors reported no significant adverse events due to treatment. Headache and flatulence occurred about equally on placebo. The abstracts have incomplete methods and safety reporting (Veljaca et al., 2002 and 2003; FDA, July 2026). | Abstracts only; no full paper |
| Ruenzi et al., 2005 (meeting abstract) | 53 adults with mild to moderate ulcerative colitis; 46 finished. | In 53 adults with ulcerative colitis, the abstract authors wrote that adverse events did not differ from placebo. Withdrawals were mainly from colitis getting worse. The abstract has limited reporting and a small short-term sample (Ruenzi et al., 2005; FDA, July 2026). | Abstract only; the FDA judged the data inadequate |
| Lee and Padgett, 2021 | 17 charts of adults with knee pain reviewed; 16 reached by phone. | In 17 charts of adults with knee pain, the authors wrote that no adverse events were noted. The charts were looked at in hindsight, with no control group, and few ways to find adverse events (Lee and Padgett, 2021). | Retrospective; follow-up varied; no control group |
| Lee et al., 2024 | 12 women aged 39 to 76 with interstitial cystitis | In 12 women with interstitial cystitis, the authors reported no adverse events and no dropouts. The pilot had no control group and was too small to show safety (Lee et al., 2024). | No control group; one small clinic series |
| Lee and Burgess, 2025 | 2 adults | In 2 healthy adults with earlier BPC-157 exposure, the authors reported no adverse events. They also reported no measurable change in heart, liver, kidney, thyroid or glucose tests. The pilot had two people and no control, so it cannot show safety (Lee and Burgess, 2025). | Two people; both had used BPC-157 before |
FAQ
What is BPC-157?
BPC-157 is a synthetic peptide of 15 amino acids, with the sequence GEPPPGKPADDAGLV. It was first described in 1993 as a fragment of a larger protein found in human gastric juice (Sikirić et al., 1993; Staresinic et al., 2003). The name stands for Body Protection Compound. The peptide has been studied mostly in lab animals. No approved medicine containing it in any country appeared in the FDA's globalEDGE search (FDA, July 2026).
Does BPC-157 cause tiredness or diarrhoea?
No BPC-157 study found for this page lists tiredness or diarrhoea as an observed side effect. But small samples cannot rule out either one. A PubMed search run on 14 October 2026 returned no BPC-157 record with fatigue in its title or abstract. Extreme tiredness appears in the TGA's list of reports for unapproved peptide products as a group. It is not linked to BPC-157 specifically (TGA, 13 April 2026). In a rat model of gut injury, diarrhoea was a sign of the untreated injury, not a side effect of the peptide. The abstract does not give group sizes, and the finding is in rats only (Vukusic et al., 2024).
Does BPC-157 affect testosterone?
No BPC-157 study that measured testosterone was found. The PubMed records searched for this page on 14 October 2026 held none. The testosterone match was a 2025 editorial that measured no hormone outcome (Dekker, 2025). BPC-157 is a synthetic peptide of 15 amino acids (FDA, July 2026). In cultured rat tendon cells, BPC-157 raised growth hormone receptor levels. The abstract gives no sample count, and this cell finding does not show a human hormone result (Chang et al., 2014). Thyroid markers did not change measurably in two healthy adults who had used BPC-157 before. That pilot was uncontrolled and cannot show hormone safety (Lee and Burgess, 2025).
How long were people exposed to BPC-157 in human studies?
Repeated exposure never passed two weeks in the FDA's list of five human studies (FDA, July 2026). A chart review of 17 knee-pain patients followed up six months to a year later, with no control group (Lee and Padgett, 2021). The 2024 bladder pilot of 12 women and the 2025 pilot of two adults reported short exposures (Lee et al., 2024; Lee and Burgess, 2025). That FDA review does not show a safety record for longer repeated exposure.
Is there a published human half-life for BPC-157?
No. The FDA's July 2026 briefing states there is no information to assess the pharmacokinetics of BPC-157 in humans. An animal study used six animals per group. The measured half-lives were 5.3 minutes in dogs and 15.2 minutes in rats. These values do not describe humans (He et al., 2022, as reported by the FDA). Two meeting abstracts covered 32 healthy male volunteers and 53 adults with ulcerative colitis. They have incomplete methods. They reported BPC-157 as not found, or mostly below the test's lowest level, in plasma (FDA, July 2026).
Is BPC-157 banned in sport?
Yes, under the World Anti-Doping Agency's rules. Its 2026 Prohibited List, with a stated effective date of 1 January 2026, names BPC-157 under S0, non-approved substances, which are prohibited at all times (WADA, 2026). That is a sport rule, separate from the Poisons Standard and from any product approval. The Australian law guide covers the Australian entries.
More in this hub
Citations
20 sourcesXu C et al. Regulatory Toxicology and Pharmacology. 2020;114:104665.
doi:10.1016/j.yrtph.2020.104665Mateescu DM et al. Pharmaceutics. 2026;18(5):625.
doi:10.3390/pharmaceutics18050625McGuire FP et al. Current Reviews in Musculoskeletal Medicine. 2025;18(12):611-619.
doi:10.1007/s12178-025-09990-7Vasireddi N et al. HSS Journal. 2025;21(4):485-495.
doi:10.1177/15563316251355551He L et al. Frontiers in Pharmacology. 2022;13:1026182.
doi:10.3389/fphar.2022.1026182Ilic S et al. Life Sciences. 2011;88(11-12):535-542.
doi:10.1016/j.lfs.2011.01.015Sikirić P et al. European Journal of Pharmacology. 1997;332(1):23-33.
doi:10.1016/s0014-2999(97)01033-9Yildirim AK et al. Journal of Clinical Medicine. 2026;15(9):3488.
doi:10.3390/jcm15093488Stupnisek M et al. Thrombosis Research. 2012;129(5):652-659.
doi:10.1016/j.thromres.2011.07.035Konosic S et al. Oxidative Medicine and Cellular Longevity. 2019;2019:9084643.
doi:10.1155/2019/9084643Hsieh MJ et al. Journal of Molecular Medicine. 2017;95(3):323-333.
doi:10.1007/s00109-016-1488-yJózwiak M et al. Pharmaceuticals. 2025;18(2):185.
doi:10.3390/ph18020185Sikiric P et al. Pharmaceuticals. 2025;18(10):1450 (comment on Józwiak et al.).
doi:10.3390/ph18101450Tewari K et al. American Journal of Sports Medicine. 2026 (online ahead of print).
doi:10.1177/03635465261464420Dekker TJ. Arthroscopy. 2025;41(8):3151-3152.
doi:10.1016/j.arthro.2025.01.033Chang CH et al. Molecules. 2014;19(11):19066-19077.
doi:10.3390/molecules191119066Vukusic D et al. Journal of Physiology and Pharmacology. 2024;75(1).
doi:10.26402/jpp.2024.1.09Sikirić P et al. Journal de Physiologie (Paris). 1993;87(5):313-327.
doi:10.1016/0928-4257(93)90038-UStaresinic M et al. Journal of Orthopaedic Research. 2003;21(6):976-983.
doi:10.1016/S0736-0266(03)00110-4Vukoja I et al. Journal of Physiology and Pharmacology. 2026;77(3):377-395.
doi:10.26402/jpp.2026.3.08
Continue
BPC-157 reference materialResearch use only: not for human or animal use.
Read the BPC-157 research guideForm Laboratories supplies research-use-only reference material. This article is an educational summary of published third-party literature. It is not medical advice, not a use instruction, and research material is not for human or animal use.
